Abstract
We describe a patient with probable dementia with Lewy bodies (DLB) whose Parkinsonism worsened after administration of rivastigmine within the therapeutic dose range. Some extrapyramidal signs (EPS) then reversed to pre-treatment level after rivastigmine dose reduction. We draw attention to the need of EPS monitoring during titration of cholinesterase inhibitors in patients with DLB. This is the first report to our knowledge of iatrogenic worsening of Parkinsonism which was successfully managed by dose reduction.
Sommario
Si descrive il caso di un paziente affetto da Demenza a corpi di Lewy (Dementia with Lewy Bodies, DLB) probabile, in cui si è assistito ad un peggioramento del parkinsonismo dopo somministrazione di rivastigmina a dosi terapeutiche. Alcuni segni extrapiramidali sono regrediti al livello pre-trattamento con una riduzione posologica di rivastigmina. Si sottolinea la necessità di un monitoraggio dei segni extrapiramidali durante la titolazione della terapia con inibitori dell’acetilcolinesterasi cerebrale in pazienti con DLB. Questo è il primo caso descritto, a nostra conoscenza, di un peggioramento iatrogeno di parkinsonismo efficacemente gestito con una riduzione posologica della terapia con rivastigmina.
Similar content being viewed by others
References
Lippa CF, Duda JE, Grossman M et al (2007) DLB and PDD boundary issues. Neurology 68:812–819
Duda JE (2004) Pathology and neurotransmitter abnormalities of dementia with Lewy bodies. Dement Geriatr Cogn Disord 17[Suppl 1]:3–14
Shea C, MacKnight C, Rockwood K (1998) Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr 10:229–238
Thomas AJ, Burn DJ, Rowan EN et al (2005) A comparison of the efficacy of donepezil in Parkinson’s disease with dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry 20:938–944
McKeith IG, Dickson DW, Lowe J et al (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872
Ballard C, O’Brien J, Swann A et al (2000) One year follow-up of parkinsonism in dementia with Lewy bodies. Dement Geriatr Cogn Disord 11:219–222
McKeith I, Del Ser T, Spano P et al (2000) Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356:2031–2036
Onofrj M, Thomas A (2003) Severe worsening of parkinsonism in Lewy body dementia due to donepezil. Neurology 61:1452
Emre M, Aarsland D, Albanese A et al (2004) Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 351:2509–2518
Iseki E (2004) Dementia with Lewy bodies: reclassification of pathological subtypes and boundary with Parkinson’s disease or Alzheimer’s disease. Neuropathology 24:72–78
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Clerici, F., Ratti, P.L., Pomati, S. et al. Cholinergic balance in dementia with Lewy bodies: reversible worsening of Parkinsonism at rivastigmine dosage modulation. Neurol Sci 28, 282–284 (2007). https://doi.org/10.1007/s10072-007-0837-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-007-0837-6